Celltrion

About Celltrion

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector.


The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.

Certifications
  • KR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Primary activities
Biopharmaceutical
Contact info
Meet us at

CPHI Barcelona 2023

Fira Barcelona Gran Via, Spain
24-26 October 2023

Celltrion Resources (1)